(177 days)
Not Found
No
The document describes standard imaging and laser photocoagulation technology with image capture, display, storage, and manipulation capabilities. There is no mention of AI, ML, or any related concepts like algorithms for automated analysis, diagnosis, or treatment planning beyond basic image processing and pattern generation for laser delivery.
Yes
The Navilas Laser System is indicated for use in various treatments like retinal photocoagulation and laser trabeculoplasty, which are therapeutic interventions.
Yes
The device's intended use explicitly states "for aiding in the diagnosis and treatment of ocular pathology in the posterior segment of the eye," and its description includes "imaging technologies (fundus live imaging, infra-red imaging and fluorescein angiography)" for "image capture, display, storage and manipulation for treatment planning and documentation." While it also performs treatment (photocoagulation), its imaging and aid in diagnosis fulfill the criteria for a diagnostic device.
No
The device description explicitly lists hardware components such as laser sources, an integrated delivery system with motorized mirrors, a digital camera, and computer hardware. The performance studies also mention both software and hardware verification and validation testing.
Based on the provided information, the Navilas Laser System is not an In Vitro Diagnostic (IVD) device.
Here's why:
- IVD Definition: In Vitro Diagnostics are devices intended for use in the examination of specimens derived from the human body (such as blood, urine, or tissue) to provide information for diagnostic purposes.
- Navilas Function: The Navilas Laser System is a medical device that combines imaging and laser treatment capabilities for the eye. It directly interacts with the patient's eye for both imaging and therapeutic procedures (photocoagulation, trabeculoplasty, iridotomy, iridoplasty).
- No Specimen Examination: The device does not examine specimens derived from the human body in a laboratory setting. Its imaging functions are performed directly on the living eye.
Therefore, the Navilas Laser System falls under the category of a therapeutic and imaging medical device, not an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
The Navilas Laser System/Navilas Laser System 532+/ Navilas Laser System 577+ are indicated for use:
· In Retinal Photocoagulation for the treatment of Clinically Significant Diabetic Macular Edema (Focal or Grid Laser), Proliferative Diabetic Retinopathy (Panretinal Photocoagulation), Sub-retinal (Choroidal) Neovascularization (Focal Laser), Central and Branch Retinal Vein Occlusion (Scatter Laser Photocoagulation, Focal or Grid Laser), Latice Degeneration, Retinal Tears and Detachments (Laser Retinopexy).
· For the imaging (capture, display, storage and manipulation) of the eve, including via color. fluorescein angiography and infrared imaging; and for aiding in the diagnosis and treatment of ocular pathology in the posterior segment of the eye.
· In Laser Trabeculoplasty for Primary Open Angle Glaucoma, as well as Iridotomy and Iridoplasty for Closed Angle Glaucoma.
Product codes (comma separated list FDA assigned to the subject device)
HGF, GEX, HKI, NFF, NFG
Device Description
The NAVILAS Laser System combines imaging technologies (fundus live imaging, infra-red imaging and fluorescein angiography) with established retinal laser photocoagulation treatment methods, providing the doctor with a system for image capture, display, storage and manipulation for treatment planning and documentation.
The primary components of the Navilas Laser System include:
- . One of three optional ophthalmic laser sources:
- a frequency doubled ND:YVO4 laser source that operates at 532nm, or -
- an optically-pumped semiconductor laser source that also operates at the same -532nm, or
- an optically-pumped semiconductor laser source that operates at 577nm -
- An integrated delivery system that directs the laser beam through ophthalmoscope optics using motorized mirrors,
- A digital camera and computer hardware that provides continuous real-time imaging ● using slit illumination that is projected through the ophthalmoscope optics and panned automatically at a rapid rate of 25 Hz across the subject area using the motorized mirrors. Imaging can be in color (using white light illumination) or in monochrome (using infrared illumination or blue light illuminations).
Laser photocoagulation with the NAVILAS can be performed using single shot (Single Spot Mode), repeated shots (Repeat Mode), and scanned patterns (Pattern Mode).
Mentions image processing
Yes
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
color, fluorescein angiography, infrared imaging
Anatomical Site
eye, posterior segment of the eye
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Performance verification and validation testing was completed to demonstrate that the device performance complies with specifications and requirements identified for the Navilas Laser System. This was accomplished by software and hardware verification & validation testing, along with system level bench testing of the Navilas Laser System. All criteria for this testing were met and results demonstrate that the Navilas Laser System meets all performance specifications and requirements.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
K091064, K123542, K071687, K091581
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 878.4810 Laser surgical instrument for use in general and plastic surgery and in dermatology.
(a)
Identification. (1) A carbon dioxide laser for use in general surgery and in dermatology is a laser device intended to cut, destroy, or remove tissue by light energy emitted by carbon dioxide.(2) An argon laser for use in dermatology is a laser device intended to destroy or coagulate tissue by light energy emitted by argon.
(b)
Classification. (1) Class II.(2) Class I for special laser gas mixtures used as a lasing medium for this class of lasers. The devices subject to this paragraph (b)(2) are exempt from the premarket notification procedures in subpart E of part 807 of this chapter, subject to the limitations in § 878.9.
0
Image /page/0/Picture/1 description: The image is a black and white logo for the U.S. Department of Health & Human Services. The logo features a stylized image of three human profiles facing right, with flowing lines above and below them. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular pattern around the image.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
January 2, 2015
OD-OS GMBH c/o Judy F. Gordon ClinReg Consulting Services, Inc. 733 Bolsana Drive Laguna Beach, CA 92651
Re: K141851
Trade/Device Name: Navilas Laser System Regulation Number: 21 CFR 878.4810 Regulation Name: Laser surgical instrument for use in general and plastic surgery and in dermatology Regulatory Class: Class II Product Code: HGF, GEX, HKI, NFF, NFG Dated: November 29, 2014 Received: December 1, 2014
Dear Dr. Gordon:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA).
You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
1
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours.
Deborah L. Falls -S
for Malvina B. Eydelman, M.D. Director Division of Ophthalmic and Ear, Nose and Throat Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K141851
Device Name Navilas Laser System
Indications for Use (Describe)
The Navilas Laser System/Navilas Laser System 532+/ Navilas Laser System 577+ are indicated for use:
· In Retinal Photocoagulation for the treatment of Clinically Significant Diabetic Macular Edema (Focal or Grid Laser), Proliferative Diabetic Retinopathy (Panretinal Photocoagulation), Sub-retinal (Choroidal) Neovascularization (Focal Laser), Central and Branch Retinal Vein Occlusion (Scatter Laser Photocoagulation, Focal or Grid Laser), Latice Degeneration, Retinal Tears and Detachments (Laser Retinopexy).
· For the imaging (capture, display, storage and manipulation) of the eve, including via color. fluorescein angiography and infrared imaging; and for aiding in the diagnosis and treatment of ocular pathology in the posterior segment of the eye.
· In Laser Trabeculoplasty for Primary Open Angle Glaucoma, as well as Iridotomy and Iridoplasty for Closed Angle Glaucoma.
| Type of Use (Select one or both, as applicable) | |
|---|---|
| ☒ Prescription Use (Part 21 CFR 801 Subpart D) | ☐ Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
4.0 510(K) SUMMARY
This 510(k) summary of safety and effectiveness information is being submitted in accordance with the requirements of 21 CFR 807.92(a).This 510(k) summary of safety and effectiveness information is being submitted in accordance with the requirements of 21 CFR 807.92(a).
4.1 SUBMITTER'S NAME, ADDRESS, TELEPHONE NUMBER, CONTACT PERSON, AND DATE SUMMARY PREPARED
| APPLICANT: | OD-OS GmbH
Warthestr. 21
14513 Teltow
Germany |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| CONTACT PERSON: | Judy Gordon, D.V.M.
ClinReg Consulting Services, Inc.
733 Bolsana Drive
Laguna Beach, CA 92651
judy@clinregconsulting.com
Tel: (949) 715-0609
Fax: (949) 715-0610 |
DATE SUMMARY PREPARED: December 22, 2014
4.2 NAME OF DEVICE, INCLUDING TRADE NAME AND CLASSIFICATION NAME
| COMMON NAME: | Photocoagulator with a Digital Camera |
|---|---|
| DEVICE CLASSIFICATION: | Laser Instrument, Surgical, Powered |
| (Class II, per 21 CFR §878.4810 | |
| Camera, Ophthalmic | |
| Class II, per 21 CFR §886.1120 | |
| Device, Storage, Images, Ophthalmic | |
| Class I per 21 CFR §892.2010 | |
| Device, Communication, Images, Ophthalmic | |
| Class I per 21 CFR §892.2020 | |
| PRODUCT CODES: | GEX; HKI, NFF, NFG |
| TRADE/PROPRIETARY NAME: | Navilas® Laser System |
4
K141851
4.3 PREDICATE DEVICES
| 510(K) # | TRADE NAME | MANUFACTURER |
|---|---|---|
| K091064 | Navilas Laser System | OD-OS |
| K123542 | PASCAL® Synthesis Ophthalmic | |
| Scanning Laser System | Topcon Medical Systems | |
| K071687 | Iridex IQ Family | Iridex |
PREDICATE DEVICES FOR NAVILAS LASER SYSTEM
PREDICATE DEVICES FOR NAVILAS LASER SYSTEM 532+
| 510(K) # | TRADE NAME | MANUFACTURER |
|---|---|---|
| K091064 | Navilas Laser System | OD-OS |
| K123542 | PASCAL® Synthesis Ophthalmic | |
| Scanning Laser System | Topcon Medical Systems | |
| K071687 | Iridex IQ Family | Iridex |
PREDICATE DEVICES FOR NAVILAS LASER SYSTEM 577+
| 510(K) # | TRADE NAME | MANUFACTURER |
|---|---|---|
| K091064 | Navilas Laser System | OD-OS |
| K123542 | PASCAL® Synthesis Ophthalmic | |
| Scanning Laser System | Topcon Medical Systems | |
| K071687 | Iridex IQ Family | Iridex |
| K091581 | Quantel Supra 577 | Quantel |
4.4 DEVICE DESCRIPTION
The NAVILAS Laser System combines imaging technologies (fundus live imaging, infra-red imaging and fluorescein angiography) with established retinal laser photocoagulation treatment methods, providing the doctor with a system for image capture, display, storage and manipulation for treatment planning and documentation.
The primary components of the Navilas Laser System include:
- . One of three optional ophthalmic laser sources:
- a frequency doubled ND:YVO4 laser source that operates at 532nm, or -
- an optically-pumped semiconductor laser source that also operates at the same -532nm, or
- an optically-pumped semiconductor laser source that operates at 577nm -
5
- An integrated delivery system that directs the laser beam through ophthalmoscope optics using motorized mirrors,
- A digital camera and computer hardware that provides continuous real-time imaging ● using slit illumination that is projected through the ophthalmoscope optics and panned automatically at a rapid rate of 25 Hz across the subject area using the motorized mirrors. Imaging can be in color (using white light illumination) or in monochrome (using infrared illumination or blue light illuminations).
Laser photocoagulation with the NAVILAS can be performed using single shot (Single Spot Mode), repeated shots (Repeat Mode), and scanned patterns (Pattern Mode).
4.5 STATEMENT OF INTENDED USE
The Navilas Laser System/Navilas Laser System 532+/ Navilas Laser System 577+ are indicated for use:
- In Retinal Photocoagulation for the treatment of Clinically Significant Diabetic Macular Edema (Focal or Grid Laser), Proliferative Diabetic Retinopathy (Panretinal Photocoagulation), Sub-retinal (Choroidal) Neovascularization (Focal Laser), Central and Branch Retinal Vein Occlusion (Scatter Laser Photocoagulation, Focal or Grid Laser), Lattice Degeneration, Retinal Tears and Detachments (Laser Retinopexy).
- . For the imaging (capture, display, storage and manipulation) of the retina of the eye, including via color, fluorescein angiography and infrared imaging; and for aiding in the diagnosis and treatment of ocular pathology in the posterior segment of the eye.
- . In Laser Trabeculoplasty for Primary Open Angle Glaucoma, as well as Iridotomy and Iridoplasty for Closed Angle Glaucoma.
TECHNOLOGICAL CHARACTERISTICS COMPARISON 4.6
The Navilas Laser System has the same indications for use, similar design and functional features and is therefore substantially equivalent to the predicate devices.
4.7 PERFORMANCE STANDARDS
The Navilas is designed, manufactured and tested in accordance with both mandatory and voluntary standards including:
- . IEC 60601-1 Medical Electric Equipment, Part 1: General requirements for safety Medical Electrical Equipment - Part 1-2: General requirements ● IEC 60601-1-2 for safety (Collateral standard: electromagnetic compatibility requirements and tests)
6
| • IEC 60601-2-22 | Medical Electrical Equipment, Part 2: Particular requirements for
the safety and diagnostic and therapeutic laser equipment |
|------------------|--------------------------------------------------------------------------------------------------------------------------------|
| • IEC 62366 | Medical Devices – Application of usability engineering to medical
devices |
| • IEC 60825-1 | Safety of Laser Products, Part 1: Equipment classification and
requirements |
| • ISO 15004-2 | Ophthalmic Instruments – Fundamental requirements and test
methods – Part 2: Light hazard protection |
| • ISO 14971 | Application of risk management to medical devices |
This device also complies with European Medical Device Directive 93/42/EEC and U.S. Federal Performance Standards per 21 CFR Part 1040 for light emitting products.
SUMMARY OF PERFORMANCE TEST RESULTS 4.8
Performance verification and validation testing was completed to demonstrate that the device performance complies with specifications and requirements identified for the Navilas Laser System. This was accomplished by software and hardware verification & validation testing, along with system level bench testing of the Navilas Laser System. All criteria for this testing were met and results demonstrate that the Navilas Laser System meets all performance specifications and requirements.
4.9 CONCLUSIONS
As described in this 510(k) Summary, all testing deemed necessary was conducted on the Navilas Laser System to ensure that the device is safe and effective for its intended use and is substantially equivalent to legally marketed devices intended for laser treatment and imaging of the eye.